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1. What is the social (and/or economic) relevance of your research results (i.e. 
in addition to the scientific relevance)? 
The research questions in this dissertation focused on evaluating community 
pharmacists’ provision of care that aims to improve patients’ use of medications. The 
research questions were grounded in the long-standing awareness of the social and 
economic costs of preventable medication-related morbidity and mortality, and the 
potential for community pharmacists to minimize these costs through provision of quality 
care and services (1). Although there has been a general awareness of the extent and 
impact of inappropriate medication use, the World Health Organization (WHO) 
catapulted this awareness to a new level in 2017 when they identified ‘Medications 
Without Harm’ as their third global patient safety challenge (2). WHO’s goal is to reduce 
the global level of severe, avoidable harm related to medications by 50% over five years, 
identifying that medications can cause serious harm if taken incorrectly or monitored 
insufficiently, or as the result of a medication-related error, accident or communication 
problem (3). WHO highlights that the global cost of medication errors alone has been 
estimated at US$ 42 billion annually and that unsafe medication practices are a leading 
cause of preventable harm around the world. Three target areas have been identified by 
WHO: high-risk situations where inappropriate medication use can cause greater harm; 
polypharmacy where patients take four or more medications, and; transitions of care 
where the risk of communication errors regarding appropriate medication use is higher.  
The alignment of these target areas with pharmacists’ traditional, acknowledged 
responsibilities for safe and effective dispensing of medications is clear. In addition, in 
many countries pharmacists are increasingly being authorized to provide, and in some 
cases reimbursed to provide, new services that take advantage of pharmacists’ potential 
to contribute more directly to achieving Medication Without Harm. These services target 
each of the prescribing, dispensing, administering, monitoring and medication use stages 
of WHO’s medication process. Medication reviews, pharmaceutical opinions, refusals to 
dispense, refill-extensions, independent prescribing, new-medicines services, medication 
reconciliation and minor ailments management are examples of services pharmacists 
have been authorized to provide to manage preventable medication-related harms. 
However, challenging and unanswered questions exist as to what pharmacists’ care and 
which of these services (if any) effectively and consistently improve medication use. 
Answers to these questions require methodologies that accurately measure both if the 
service was provided and the quality of service provided, and that evaluate the impact on 
outcomes important to patients and health care systems. Only when such methodologies 
have been developed can an understanding be gained of pharmacists’ services that 
consistently decrease medication-related harms and of the strategies that improve the 
quality and impact of these services. Development and evaluation of these 
methodologies are the core questions addressed in this dissertation.  
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2. To whom, in addition to the academic community, are your research results 
of interest and why? 
Pharmacy regulatory authorities are the stakeholders most directly interested in the 
results of our research as they are responsible for ensuring the safe and effective practice 
of licensed pharmacists with focus on protection of the public. In many countries, a 
component of this responsibility is the mandatory requirement for assurance of 
pharmacists’ continuing competence to practice. The framework developed and 
evaluated for this dissertation stemmed directly from earlier work with the Canadian 
National Association of Pharmacy Regulatory Authorities (NAPRA) and was designed 
specifically for use by regulatory authorities for quality assurance of community 
pharmacists’ practice.  
Health quality assurance organizations, that have been developed on a national and 
provincial level, represent a second group of organizations interested in the results of this 
research. Most of these organizations have developed indicators that are used to 
evaluate the quality and impact of care provided by a range of health care professionals. 
As evidence and awareness grew of both the costs associated with preventable 
medication-related harms and the potential for management of these costs by 
pharmacists, interest in community pharmacy quality-of-care metrics and systems 
increased. In Ontario, the pharmacy regulatory authority (the Ontario College of 
Pharmacists, OCP) has partnered with the provincial health quality assurance 
organization (Health Quality Ontario, HQO) with the goal of developing four to five 
indicators that measure pharmacy practice quality and system-level impact (4). Results 
of our research were relied upon in the preparatory discussion for development of these 
indicators and, as described below, in the round-table discussion held in 2018. 
Public and private payers of medications are a third group interested in the results of this 
research, particularly related to the methodologies developed to evaluate the impact of 
new pharmacists’ services. The need for such evaluation systems has been identified by 
these stakeholders across Canada with interest expressed in our methodologies at both 
the provincial and federal level. Provincial payers have acknowledged making a leap of 
faith when agreeing to authorize and fund pharmacists’ provision of professional services 
targeted at improving use of medications (5). In the absence of an accepted, evidence-
based pharmacist-service evaluation framework, there is only limited and inconsistent 
evidence available documenting the impact of pharmacists’ services. Private and public 
payers are responding to this lack of evidence by limiting and, in some cases, reversing 
decisions to fund pharmacists’ provision of these services (6, 7).  
Pharmacy advocacy organizations and pharmacy owners are the final interested group, 
the former of which represent practicing pharmacists on a national (i.e. Canadian 
Pharmacists’ Association (CPhA)) or provincial (e.g. Ontario Pharmacists’ Association) 
level. Chapter 3 presented a targeted effort to translate our research findings into 
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pharmacy practice. We used the barriers and facilitators identified via our continuing 
professional development framework to analyze the development and implementation 
of a well-recognized, quality pharmacists’ travel health service. Published in CPhA’s 
journal, this article was identified as a benchmark process to be used by pharmacists 
interested in implementing new services.  
In addition to use of the framework for introducing new services, our methodologies 
for evaluating the impact of pharmacists’ services are of particular relevance to these 
organizations and to pharmacy owners. To counter the actions of public and private 
payers to limit /reverse payment authorizations for pharmacists’ services, pharmacy 
advocacy organizations and owners require robust evidence of the impact of these 
services.  
3. Into which concrete products, services, processes, activities or commercial 
activities will your results be translated and shaped? 
The preliminary nature of the research conducted for this dissertation limits the 
translation of results into concrete products or commercial activities, especially given 
that results highlight the shortage of evidence confirming the consistent impact of 
pharmacists’ services on patient outcomes. However, our research results are influencing 
and being translated into the processes and activities of the four stakeholder groups as 
follows: 
Pharmacy regulatory authorities: Results of our research were highlighted in 2018 at a 
national invitational meeting hosted by the pharmacy regulatory authority of Nova Scotia. 
This conference addressed the use of complexity theory to address the problem of how 
community pharmacists’ practice could consistently and efficiently be transitioned to 
focus on improving patient’s use of medications (8). Among presentations on 
pharmacists’ attitudes, professional identity and reviews of evidence, our research results 
highlighted the need for measurement systems and indicators that are consistent with 
health systems’ priorities and that measure what matters most to patients.  
In follow-up to the April 2018 meeting, the Nova Scotia College of Pharmacists 
identified a number of undertakings related to community pharmacy quality metrics as 
part of their 2019 strategic plan. These include identifying how patients expect the status 
quo of their health to be impacted by the care they receive from a pharmacist, a summary 
of potential pharmacy quality-of-care indicators and a review of the evidence to support 
these indicators. As per the strategic plan, these undertakings aim to contribute to the 
development of policies that improve the Nova Scotia health care system by ensuring 
that the practice of pharmacy aligns with evolving patient care needs. Negotiations are 
presently underway for collaboration with the Nova Scotia College of Pharmacists to 
complete these undertakings including use of the results of this dissertation and the 
expertise gained via completion of the associated research projects and analysis. 
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Health quality assurance organizations: The introduction, analysis and research results 
from this dissertation served as the basis for the backgrounder written for the invitation-
only roundtable hosted by OCP and HQO in May of 2018. This event built upon lessons 
learned to achieve consensus on a set of principles to guide the identification of 
pharmacy quality indicators for public reporting (9). Ideally this work will lead to the 
incorporation of measurement and reporting of pharmacists’ care into HQO’s existing 
suite of quality reports and resources (10). These include confidential and customized 
reports provided to family physicians that could potentially be modified to provide similar 
reports to community pharmacists. In addition, yearly public reports on the performance 
of Ontario’s health system are created that could potentially incorporate indicators 
measuring quality of pharmacists’ care (11). 
Discussions are ongoing with these organizations to determine the next steps in 
incorporating the results of our research into the processes for both identifying 
appropriate community pharmacists’ quality of care indicators and developing 
methodologies for using performance on these indicators to improve pharmacists’ 
quality of care.  
Public and private payers of medications: The Ontario Pharmacy Research Collaboration 
(OPEN) received $5.7 million (Canadian dollars) in 2013 from the Ontario Ministry of 
Health and Long-Term Care Health System Research Fund to study the quality, outcomes 
and value of pharmacists’ services (12). Results of our research projects informed the 
funding proposal for the project related to development of a pharmacists’ services 
evaluation framework. Initial results of this work identified that development of this 
evaluation framework is a key priority across Canada, confirmed that no comprehensive, 
functioning pharmacy evaluation frameworks were available, and determined that 
priorities for evaluating methodologies were inconsistent across stakeholders (13, 14).  
Results of our research continued to inform the work of OPEN via the 2014 invitational 
meeting where the use of quality indicators in community pharmacy was introduced as a 
methodology to both measure community pharmacists’ quality of care and evaluate the 
impact of new pharmacists’ services (15). This lead to a Canadian Institute of Health 
Research grant to OPEN for a symposium entitled “Incorporating Quality Improvement 
into Community Pharmacy to Improve Drug Prescribing, Use and Health Outcomes for 
Older Adults” (16). Results of our research projects were presented as the keynote 
address at this conference (17). Learnings from this dissertation continue to serve as 
background to guide ongoing OPEN research projects, including those recently funded 
via an additional $2 million (Canadian dollars) from the Ontario Ministry of Health and 
Long-Term Care Health System Research Fund (18).  
In addition to interest from public payers, a key Canadian private insurer attended the 
2014 presentation of our research results at the OPEN provincial meeting and 
subsequently expressed interest in developing a pharmacy quality measurement system 
for use within their insurance group. Follow-up led to Green Shield Canada insurance 
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group’s introduction to the Pharmacy Quality Alliance (PQA) and subsequent partnership 
with PQA’s Pharmacy Quality Solutions (PQS) to introduce Green Shield’s Value Based 
Pharmacy program in Canada (19, 20). This program provides audit and feedback of 
pharmacy-level performance on selected quality indicators. Green Shield Canada has 
recently published their plans for performance improvement which include: Phase 1 
provision of comparative feedback alone, Phase 2 pharmacy-level performance results 
available publicly via the internet for pharmacy selection, and Phase 3 variable dispensing 
fee reimbursements dependent on indicator performance (21).  
As discussed in this dissertation, methodological questions remain regarding the 
appropriateness of the measures used within Green Shield Canada’s program, the validity 
of assessment results for comparison purposes, and the evidence supporting 
pharmacists’ capacity to improve their performance and to impact on patient outcomes. 
However, introduction of Green Shield Canada’s commercial activity has piqued 
regulatory and professional interest in the appropriate selection of pharmacy quality 
metrics and methodologies for robust measurement and improvement in community 
pharmacists’ performance. As no other research is ongoing in this area in Canada, our 
methodologies / indicators / recommendations are being considered by at least two 
provinces for use in development of more robust quality assurance programs. 
Pharmacy advocacy organizations: The Canadian Pharmacists Association (CPhA) recently 
embarked upon a process to develop a forward-thinking, uniform national scope of 
practice for the profession of pharmacy across Canada (22). In follow-up to presentation 
of our research results and recommendations at the Nova Scotia College of Pharmacists’ 
meeting, CPhA requested discussion regarding the definition and measurement of 
pharmacists’ quality of care. Advocacy organizations are aware that in the absence of a 
nationally agreed upon, pragmatic, evidence-based definition of quality pharmacists’ 
care, disparate and potentially self-serving definitions and metrics could be developed 
and applied across Canada.  
4. To what degree can your results be called innovative in respect to the existing 
range of products, services, processes, activities and commercial activities? 
Availability of detailed and linked administrative health data that included billing records 
for dispensings of medications and community pharmacists’ services, access to a 
population-based sample of pharmacies and robust data analysis methodologies make 
this research unique in the world.  Although the PQA has developed commercial systems 
for measuring and reporting pharmacy level performance across selected metrics in the 
USA, the primary stakeholder for this US-based work was the insurance industry (i.e. 
private payers).  Green Shield Canada has recently introduced a PQA-based reporting 
system, adopting the PQA-insurance focus with less emphasis on evaluating the 
methodologies used by PQA / PQS or the theories underlying the measurement and 
improvement of pharmacists’ quality of care.  By contrast, these have been the focus of 
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the research completed for this dissertation, with emphasis on determining the 
requirements for appropriate selection and use of pharmacy quality metrics to improve 
both pharmacists’ performance and patients’ use of medications.  
A number of countries have developed indicators aiming to measure the quality of 
pharmacists’ care, with the Netherlands leading work including evaluation of the validity 
of their proposed indicators.  However, despite ongoing work in the Netherlands, the 
USA, UK, the Organization for Economic Co-operation and Development (OECD) and the 
Pharmaceutical Care Network of Europe, recent reviews document a continuing lack of 
well-developed, validated indicators for measurement of the processes and outcomes of 
pharmacists’ quality of care.  The results of our analysis that indicated the need to re-
evaluate the indicators most frequently selected as measures of pharmacists’ quality of 
care have been adopted as best practice by the two pharmacy regulatory authorities 
working in this area in Canada. Our recommendations to both select indicators important 
to patients and health care systems, and to carefully evaluate the literature reporting on 
the impact of pharmacists’ services on these indicators, formed the basis for ongoing 
strategic initiatives by the NSCP.  
The detailed, coded data in our administrative health databases of pharmacists’ 
service provision addressed the challenge faced by many countries of lack of 
documentation of service provision.  Early work such as that in the Netherlands relied on 
self-report by pharmacists of services provided while the research in this dissertation 
capitalized upon the province of Quebec’s long history of both reimbursing pharmacists 
for professional services and requiring service details for reimbursement.  As pharmacists 
are increasingly being reimbursed to provide services, the methodologies developed via 
our research can be used to evaluate the impact of these services.  Further, the 
methodologies developed for direct measurement of pharmacy characteristics from 
administrative health data and multi-level analysis of determinants of quality of care 
represent first published results.  Our research results are, therefore, innovative and 
standard-setting for ongoing pharmacy-services’ evaluation research and policy-
initiatives at both provincial and federal levels. 
5. How will this/these plan(s) for valorization be shaped? What is the schedule, 
are there risks involved, what market opportunities are there and what are the 
costs involved? 
The primary factor shaping plans for valorization of our research results is market 
realization. The need for stakeholders to embark upon strategic initiatives related to 
defining and measuring pharmacists’ quality and impact of care has been described. The 
more challenging question is whether pharmacy stakeholders acknowledge the breadth 
of these needs and/or the need for expertise and ongoing research to adequately address 
these strategic initiatives. Creation of policy is the focus of many of the relevant 
stakeholders, and policy development can be strongly influenced by political process and 
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administrative requirements. Consensus building can take priority with a tendency to 
focus on inclusivity rather than expertise. Therefore, risks include that work to identify 
evidence-based definitions of quality pharmacists’ practice and community pharmacy 
quality-of-care metrics could be caught up in political processes and consensus building 
that is not necessarily evidence-based. This risk is exacerbated by the tendency of the 
profession to rely on pharmacy-only working groups and pharmacy-centric evidence for 
development of core policies (23). Core evidence and expertise may not be not 
considered (24), such as Mossialos et al’s article on the lack of policy-relevant evidence 
to support the expanding role of the community pharmacist (25) or relevant, robust 
systematic reviews from the Cochrane Database (26, 27).  
Increasing recognition of the potential for pharmacists to improve medication use is, 
however, creating new opportunities for both implementation of results of this 
dissertation and ongoing research. Funds such as those for medication optimization 
projects via the Frailty Network provide opportunities for further research (28). Ongoing 
collaboration with regulatory authorities offers more direct opportunities for knowledge 
translation and development of policies based on and further expanding the results of 
this dissertation.  
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